Business Context and Reporting Period
Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical company focused on developing medicines using proprietary oral film (PharmFilm) and epinephrine prodrug (Adrenaverse) technologies. The company operates as a single segment, manufacturing licensed products and developing proprietary candidates. This summary covers the fiscal year ended December 31, 2024.
- Key Product Launch: Libervant (diazepam) Buccal Film was launched in April 2024 for pediatric epilepsy patients (ages 2-5).
- Key Pipeline: Anaphylm (epinephrine) Sublingual Film for anaphylaxis; AQST-108 (epinephrine) Topical Gel for alopecia areata.
- Manufacturing: Exclusive manufacturer of licensed products (e.g., Suboxone) and proprietary products at facilities in Portage, Indiana.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $57.6 million | $50.6 million | +14% |
| Net Loss | $(44.1) million | $(7.9) million | Widened significantly |
| Loss Per Share (Diluted) | $(0.51) | $(0.13) | - |
| Cash and Cash Equivalents | $71.5 million | $23.9 million | +199% |
| Operating Cash Flow | $(35.8) million | $(6.4) million | Increased outflow |
| Long-Term Debt (13.5% Notes) | $45.0 million | $45.0 million | Stable |
| Accumulated Deficit | $(363.2) million | $(319.1) million | - |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased 14% primarily due to a one-time recognition of $11.5 million in deferred revenue from terminated licensing agreements (Haisco and MTPA). Manufacture and supply revenue decreased 9% due to lower Suboxone volumes and the absence of retroactive price adjustments recognized in 2023.
- Expense Growth:
- R&D Expenses: Increased 55% to $20.3 million, driven by clinical trial costs for Anaphylm and AQST-108.
- SG&A Expenses: Increased 58% to $50.2 million, reflecting higher commercial spending for Libervant, severance costs, and share-based compensation.
- Interest Expense: Increased 76% to $11.1 million, largely due to the full-year amortization of the 13.5% Notes issued in late 2023.
- Liquidity Position: Cash balances more than tripled to $71.5 million, bolstered by a $72.9 million underwritten public offering in Q1/Q2 2024 and $11.8 million from ATM sales.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance
- Anaphylm: NDA submission commenced in Q1 2025. FDA pre-NDA feedback was positive. Launch targeted for Q1 2026 if approved.
- Libervant: Commercialization ongoing for ages 2-5. Company is seeking to overcome orphan drug exclusivity blocks for patients aged 6+ (currently blocked until Jan 2027).
- Capital Needs: Management expects to incur significant losses and negative cash flows for the foreseeable future. Additional capital will be required to fund operations, debt service, and commercialization.
Material Risks and Contingencies
- Libervant Litigation (Critical): On February 14, 2025, a U.S. District Court ruled in favor of competitor Neurelis, vacating the FDA's approval of Libervant for patients aged 2-5. The court ruled that the orphan drug exclusivity for Neurelis's Valtoco (approved for ages 6+) extends to the younger population. Aquestive has appealed and filed a motion to stay the ruling. The company continues to market Libervant pending the appeal outcome.
- Customer Concentration: Indivior (Suboxone) accounted for 62% of 2024 revenue. The agreement is subject to annual renewal and potential termination.
- Debt Obligations: The company has $45 million in 13.5% Senior Secured Notes due 2028. Principal amortization begins in June 2026. Failure to meet debt covenants could result in default.
- Going Concern: While the company has sufficient liquidity for the next 12 months, it has a history of net losses and an accumulated deficit of $363.2 million.
Investor Verification Checklist
- Libervant Legal Status: Verify the status of the appeal regarding the February 2025 court order vacating Libervant's FDA approval and the potential impact on current and future revenue.
- Suboxone Revenue Trend: Monitor the decline in Suboxone volumes and the expiration of patent protections, which drives the majority of current cash flow.
- Anaphylm NDA Timeline: Confirm the submission date and FDA review timeline for the Anaphylm NDA, as this is the primary growth driver.
- Debt Service Capacity: Assess the company's ability to service the 13.5% Notes (interest-only until 2026) given the high burn rate and lack of profitability.
- Capital Raise Activity: Track utilization of the At-The-Market (ATM) facility and potential dilution from future equity offerings.